BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ko AH. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol. 2007;34:354-364. [PMID: 17674964 DOI: 10.1053/j.seminoncol.2007.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhang T, Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother. 2009;58:475-492. [PMID: 18925393 DOI: 10.1007/s00262-008-0598-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
2 Gong DJ, Zhang JM, Yu M, Zhuang B, Guo QQ. Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma. Clin Interv Aging. 2013;8:889-897. [PMID: 23898224 DOI: 10.2147/cia.s45064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Mauro LV, Grossoni VC, Urtreger AJ, Yang C, Colombo LL, Morandi A, Pallotta MG, Kazanietz MG, Bal de Kier Joffé ED, Puricelli LL. PKC Delta (PKCdelta) promotes tumoral progression of human ductal pancreatic cancer. Pancreas 2010;39:e31-41. [PMID: 19924022 DOI: 10.1097/MPA.0b013e3181bce796] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
5 Cirigliano SM, Mauro LV, Grossoni VC, Colombo LL, Diament MJ, Kazanietz MG, Bal de Kier Joffé ED, Puricelli LI, Urtreger AJ. Modulation of pancreatic tumor potential by overexpression of protein kinase C β1. Pancreas 2013;42:1060-9. [PMID: 23695799 DOI: 10.1097/MPA.0b013e31828fd141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
7 You L, Chang D, Du HZ, Zhao YP. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. Biochem Biophys Res Commun. 2011;407:1-6. [PMID: 21316338 DOI: 10.1016/j.bbrc.2011.02.027] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 8.3] [Reference Citation Analysis]
8 Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 2009;8:125. [PMID: 20021699 DOI: 10.1186/1476-4598-8-125] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 6.7] [Reference Citation Analysis]